2,2'-azobis(2-amidinopropane) has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviram, M; Hussein, O; Keidar, S; Rosenblat, M; Schlezinger, S | 1 |
| Suzuki, T; Suzumura, K; Tanaka, K; Yasuhara, M | 1 |
2 other study(ies) available for 2,2'-azobis(2-amidinopropane) and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
Topics: Adult; Aged; Amidines; Anticholesteremic Agents; Copper Sulfate; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Free Radical Scavengers; Humans; Hypercholesterolemia; Indoles; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Middle Aged | 1997 |
Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro.
Topics: Adult; Amidines; Antioxidants; Copper; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Male; Oxidants; Oxidation-Reduction; Structure-Activity Relationship; Vitamin E | 1999 |